Search
Gremubamab
go.drugbank.com/drugs/DB15014InvestigationalGremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
Categories: Amino Acids, Peptides, and ProteinsAcadesine
go.drugbank.com/drugs/DB04944InvestigationalIt is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing
Categories: Nucleic Acids, Nucleotides, and NucleosidesLarazotide
go.drugbank.com/drugs/DB05645InvestigationalAn octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.
Categories: Amino Acids, Peptides, and ProteinsNeisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10799ApprovedInvestigationalNeisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … grown in another culture.
Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10800ApprovedInvestigationalNeisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … grown in another culture.
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigational[L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic … Gedatolisib is a kinase inhibitor that blocks all four class I PI3K isoforms together with both mTOR complexes, mTORC1 and mTORC2, producing downstream inhibition of multiple effectors including AKT.
Categories: Antineoplastic and Immunomodulating Agents, Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitorsDiphemanil
go.drugbank.com/drugs/DB13720ApprovedVet approvedWithdrawnSynonyms: Diphemanil ionCategories: Alimentary Tract and Metabolism, diphemanil and psycholepticsCaroxazone
go.drugbank.com/drugs/DB09254ApprovedWithdrawnCaroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. … However, it presents a five-fold preference for the MAO-B subtype.
Olokizumab
go.drugbank.com/drugs/DB13127InvestigationalInterleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. … Targeting IL-6 function can be achieved directly, or through interrupting the IL-6 receptor or gp130 receptor axes.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsLX1031
go.drugbank.com/drugs/DB05199InvestigationalLX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. … LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system
Categories: Amino Acids, Peptides, and Proteins